Update on the use of deferasirox in the management of iron overload

References

• PorterJBPractical management of iron overloadBr J Haematol2001115223925211703317
   PubMed Web of Science ®Google Scholar
• PootrakulPKitcharoenKYansukonPThe effect of erythroid hyperplasia on iron balanceBlood1988714112411293355891
   PubMed Web of Science ®Google Scholar
• GabuttiVPigaAResults of long-term iron-chelating therapyActa Haematol199695126368604584
   PubMed Web of Science ®Google Scholar
• OlivieriNFNathanDGMacMillanJHSurvival in medically treated patients with homozygous β-thalassemiaN Engl J Med199433195745788047081
   PubMed Web of Science ®Google Scholar
• OlivieriNFBrittenhamGMIron-chelating therapy and the treatment of thalassemiaBlood19978937397619028304
   PubMed Web of Science ®Google Scholar
• DeleaTEEdelsbergJSofryginOConsequences and costs of non compliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature reviewTransfusion200747101919192917880620
   PubMed Web of Science ®Google Scholar
• Ferriprox. Summary of Product Characteristics. Apotex; 1999
   Google Scholar
• CeciABaiardiPFelisiMThe safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patientsBr J Haematol2002118133033612100170
   PubMed Web of Science ®Google Scholar
• CohenARGalanelloRPigaADe SanctisVTrictaFSafety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood200310251583158712763939
   PubMed Web of Science ®Google Scholar
• Duffy-WarrenFChesiARigourdSFrederickAExjade® (deferasirox) Basic Prescribing InformationURL http://wwwexjadecom/indexjsp2008
   Google Scholar
• NickHAcklinPLattmannRDevelopment of tridentate iron chelators: from desferrithiocin to ICL670Curr Med Chem200310121065107612678677
   PubMed Web of Science ®Google Scholar
• SteinhauserSHeinzUBartholomaMWeyhermüllerTNickHHegetschweilerKComplex formation of ICL670 and related ligands with FeIII and FeIIEur J Inorg Chem20042141774192
   Web of Science ®Google Scholar
• GlicksteinHElBRLinkGAction of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequencesBlood200610893195320316835377
   PubMed Web of Science ®Google Scholar
• WoodJCOtto-DuesselMGonzalesIDeferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbilTransl Res2006148527228017145573
   PubMed Web of Science ®Google Scholar
• NickHWongAAcklinPICL670A: preclinical profileAdv Exp Med Biol200250918520312572995
   PubMed Web of Science ®Google Scholar
• PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica200691787388016818273
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAAlbertiDRouanMCBiglerHSechaudRSafety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemiaJ Clin Pharmacol200343656557212817519
   PubMed Web of Science ®Google Scholar
• Nisbet-BrownEOlivieriNFGiardinaPJEffectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialLancet200310361(9369):1597160212747879
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaACappelliniMDEffect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimenJ Clin Pharmacol200848442843518281442
   PubMed Web of Science ®Google Scholar
• CappelliniMDCohenAPigaAA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemiaBlood200610793455346216352812
   PubMed Web of Science ®Google Scholar
• GalanelloRPigaAForniGLPhase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia majorHaematologica200691101343135117018383
   PubMed Web of Science ®Google Scholar
• PorterJGalanelloRSaglioGRelative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective studyEur J Haematol200880216817618028431
   PubMed Web of Science ®Google Scholar
• VichinskyEOnyekwereOPorterJA randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseBr J Haematol2007136350150817233848
   PubMed Web of Science ®Google Scholar
• TaherAEl-BeshlawyAElalfyMSEfficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR studyEur J Haematol200982645846519187278
   PubMed Web of Science ®Google Scholar
• TaherAEl-BeshlawyAElalfyMDeferasirox significantly reduces iron burden in heavily iron-overloaded patients with beta-thalassaemia: 2.7 year results from the ESCALATOR studyHaematologica200994Suppl 2abstr 209.
   Google Scholar
• CappelliniMDPorterJEl-BeshlawyATailoring iron chelation by iron intake and serum ferritin: Prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasHaematologica2009In press.
   Web of Science ®Google Scholar
• CohenARGlimmEPorterJBEffect of transfusional iron intake on response to chelation therapy in β-thalassemia majorBlood2008111258358717951527
   PubMed Web of Science ®Google Scholar
• CappelliniMDGalanelloRPigaAEfficacy and safety of deferasirox (Exjade®) with up to 4.5 years of treatment in patients with thalassemia major: a pooled analysisBlood200811211abstr 5411.
   PubMed Web of Science ®Google Scholar
• PigaAForniGLKattamisADeferasirox (Exjade®) in pediatric patients with β-thalassemia: update of 4.7-year efficacy and safety from extension studiesBlood200811211abstr 3883.
   Web of Science ®Google Scholar
• CappelliniMDElalfyMSKattamisAEfficacy and safety of once-daily, oral iron chelator deferasirox (Exjade®) in a large group of regularly transfused patients with β-thalassemia majorBlood200811211abstr 3878.
   PubMed Web of Science ®Google Scholar
• GattermannNSchmidMDella PortaMEfficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trialBlood200811211abstr 633.
   Web of Science ®Google Scholar
• LeeJWYoonSSShenZXIron chelation in regularly transfused patients with aplastic anemia: efficacy and safety results from the large deferasirox EPIC trialBlood200811211abstr 439.
   Web of Science ®Google Scholar
• PorterJBLinKHHabrDDomokosGHmissiATheinSLDeferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemiasBlood200811211abstr 1419.
   Web of Science ®Google Scholar
• PorterJBForniGLBerisPEfficacy and safety of 1 year’s treatment with deferasirox (Exjade®): assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC studyBlood200811211abstr 1048.
   Web of Science ®Google Scholar
• TaherACappelliniMDVichinskyEEfficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overloadBr J Haematol2009[Epub ahead of print].
   Web of Science ®Google Scholar
• Borgna-PignattiCRugolottoSDe StefanoPSurvival and complications in patients with thalassemia major treated with transfusion and deferoxamineHaematologica200489101187119315477202
   PubMed Web of Science ®Google Scholar
• PathareATaherADaarSDeferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia majorAnn Hematol2009[Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• RoghiACassinerioEProtoPThe effect of deferasirox on myocardial iron overload and cardiac function: a prospective independent monocentric study using cardiovascular magnetic resonance T2* (MRI T2*)Haematologica200994Suppl 2abstr 762.
   Google Scholar
• WoodJThompsonAPaleyCDeferasirox reduces cardiac iron burden in chronically transfused β-thalassemia patients with mild-to-moderate cardiac siderosis as demonstrated by MRI T2*Haematologica200994Suppl 2abstr 763.
   PubMedGoogle Scholar
• EleftheriouPTannerMPennellDPorterJBResponse of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysisHaematologica200691Suppl 1abstr 999.
   Google Scholar
• PennellDPorterJBCappelliniMDEfficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trialBlood200811211abstr 3873.
   Web of Science ®Google Scholar
• PennellDSutcharitchanPEl-BeshlawyAEfficacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trialBlood200811211abstr 3874.
   Web of Science ®Google Scholar
• LadisVBerdoussiHKattamisATreatment with deferasirox for non-transfusional iron overload in patients with thalassemia intermediaHaematologica200994Suppl 2abstr 1279.
   Google Scholar
• VoskaridouEKonstantinidouMDouskouMTreatment with deferasirox effectively decreases iron burden in patients with thalas-semia intermediaHaematologica200994Suppl 2abstr 204.
   PubMedGoogle Scholar
• GreenbergPLSchifferCKollerCAGlynosTPaleyCChange in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patientsBlood200811211abstr 5083.
   PubMedGoogle Scholar
• ListAFBaerMRSteensmaDIron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS)Blood200811211abstr 634.
   Web of Science ®Google Scholar
• WimazalFNosslingerTBaumgartnerCSperrWRPfeilstockerMValentPDeferasirox induces regression of iron overload in patients with myelodysplastic syndromesEur J Clin Invest20093940641119320908
   PubMed Web of Science ®Google Scholar
• MinYHKimHJLeeKHA multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRIBlood200811211abstr 3649.
   Web of Science ®Google Scholar
• MessaECilloniDMessaFDeferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosisActa Haematol20081202707418827475
   PubMed Web of Science ®Google Scholar
• GattermannNSchmidMGuerci-BreslerAReduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in iron overloaded patients with myelodysplastic syndromes (MDS)Leuk Res200933Suppl 1S140S141(abstr P140).
   PubMed Web of Science ®Google Scholar
• DeleaTEHagiwaraMPhatakPDRetrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disordersCurr Med Res Opin200925113914719210147
   PubMed Web of Science ®Google Scholar
• SchaferAICheronRGDluhyRClinical consequences of acquired transfusional iron overload in adultsN Engl J Med198130463193246777701
   PubMed Web of Science ®Google Scholar
• BennettJMConsensus statement on iron overload in myelodysplastic syndromesAm J Hematol20088385886118767130
   PubMed Web of Science ®Google Scholar
• GattermannNPorterJLopesLFConsensus statement on iron overload in myelodysplastic syndromesHematol Oncol Clin North Am200519Suppl 11825
   Google Scholar
• VichinskyECoatesTThompsonAADeferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-upBlood200811211abstr 1420.
   Web of Science ®Google Scholar
• CancadoROlivatoMCBrunieraPChiattoneCDeferasirox for the treatment of transfusional iron overload in sickle cell anemia: a 1-yr prospective studyHaematologica200994Suppl 2abstr 210.
   Google Scholar
• VoskaridouEDouskouMPlataETreatment with deferasirox effectively decreases iron burden in patients with sickle cell syndromesHaematologica200994Suppl 2abstr 215.
   PubMedGoogle Scholar
• RoseCGattermannNGlimmERabaultBDeferasirox (Exjade, ICL670), the novel, once-daily oral iron chelator, is well tolerated and effective in treating transfusional iron overload in patients with a range of rare anaemiasHaematologica200691Suppl 1abstr 22.
   Google Scholar
• TcherniaGVichinskyEJengMThe once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patientsHaematologica200590Suppl 2192
   Google Scholar
• PigaAKebailiKGalanelloRCumulative efficacy and safety of 5-year deferasirox (Exjade®) treatment in pediatric patients with thalassemia major: a Phase II multicenter prospective trialBlood200811211abstr 5413.
   Web of Science ®Google Scholar
• TaherAAl JefriAElalfyMSDeferasirox (Exjade®) treatment in pediatric β-thalassemia patients with high iron burden: 2.8 years results from ESCALATOR trialBlood200811211abstr 3879.
   Web of Science ®Google Scholar
• KruszewskiMThe role of labile iron pool in cardiovascular diseasesActa Biochim Pol200451247148015218543
   PubMed Web of Science ®Google Scholar
• EspositoBPBreuerWSirankaprachaPLabile plasma iron in iron overload: redox activity and susceptibility to chelationBlood20031022670267712805056
   PubMed Web of Science ®Google Scholar
• DaarSPathareANickHReduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemiaEur J Haematol200982545445719191863
   PubMed Web of Science ®Google Scholar
• PorterJBCappelliniMDEl-BeshlawyAEffect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trialBlood200811211abstr 3881.
   Web of Science ®Google Scholar
• GhotiHFibachEMerkelDDecrease in intra- and extra-cellular free iron species and oxidative stress parameters and increase in serum and urinary hepcidin during treatment with deferasirox in iron-loaded patients with MDSHaematologica200994Suppl 2abstr 797.
   Google Scholar
• BennettWPonticelliCPigaAKattamisAGlimmEFordJSummary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670)Blood200610811abstr 3816.
   Web of Science ®Google Scholar
• KuczmarskiRJOgdenCLGrummer-StrawnLMCDC growth charts: United StatesAdv Data200031412711183293
   PubMedGoogle Scholar
• VichinskyECoatesTThompsonASafety and efficacy of iron chelation therapy with deferasirox in patients with sickle cell disease (SCD): 3.5-year follow-upHaematologica200994Suppl 2abstr 200.
   Google Scholar
• OlivieriNFBuncicJRChewEVisual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusionsN Engl J Med1986314148698733485251
   PubMed Web of Science ®Google Scholar
• PorterJBJaswonMSHuehnsEREastCAHazellJWDesferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosageBr J Haematol19897334034092605127
   PubMed Web of Science ®Google Scholar
• PorterJBPigaACohenAFordJMBodnerJCappelliniMDAssessment of safety in patients receiving longer-term iron chelation therapy with deferasirox who had achieved serum ferritin levels of <1000 ng/mL during the study courseHaematologica200994Suppl 2abstr 199.
   PubMedGoogle Scholar
• PorterJBPigaACohenASafety of deferasirox (Exjade®) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels <1000 ng/mL during long-term treatmentBlood200811211abstr 5423.
   Web of Science ®Google Scholar
• BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med199433195675738047080
   PubMed Web of Science ®Google Scholar
• RenfroeJLForbesPBraunsteinJNeufeldEJRelationship of transfusion and iron-related complications to cost of care in thalassemiaBlood200510611abstr 2240.
   Web of Science ®Google Scholar
• DeleaTESofryginOThomasSKBaladiJFPhatakPDCoatesTDCost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. US healthcare system perspectivePharmacoeconomics200725432934217402805
   PubMed Web of Science ®Google Scholar
• KarnonJTolleyKOyeeJJewittKOssaDAkehurstRCost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United KingdomCurr Med Res Opin20082461609162118439348
   PubMed Web of Science ®Google Scholar
• CappelliniMDBejaouiMAgaogluLProspective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemiaClin Ther200729590991717697909
   PubMed Web of Science ®Google Scholar
• PorterJBBowdenDGanserASatisfaction and adherence significantly improves in patients with β-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade®)Blood200811211abstr 1306.
   Web of Science ®Google Scholar
• TaherAAl JefriAElalfyMImproved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with β-thalassemia: Results from ESCALATOR trialHaematologica200893Suppl 1abstr 799.
   Google Scholar
• VichinskyEPakbazZOnyekwereOPatient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trialActa Haematol2008119313314118408362
   PubMed Web of Science ®Google Scholar
• PorterJBBowdenDGanserAImproved health-related quality of life in patients with hematological disorders receiving deferasirox (Exjade®)Blood200811211abstr 1307.
   Web of Science ®Google Scholar
• AldouriMAWonkeBHoffbrandAVHigh incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelationActa Haematol19908431131172123060
   PubMed Web of Science ®Google Scholar
• AndersonLJWestwoodMAHoldenSMyocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBr J Haematol2004127334835515491298
   PubMed Web of Science ®Google Scholar
• DavisBAPorterJBLong-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemiaBlood20009541229123610666195
   PubMed Web of Science ®Google Scholar